New hope for lymphoma patients when CAR-T fails: tailored drug cocktail shows promise

Copied word for word from the study's registry entry, so the wording is the study team's rather than ours.

Inclusion Criteria: * Age ≥ 18 years, regardless of gender. * Histologically confirmed large B-cell lymphoma (LBCL), including diffuse large B-cell lymphoma (DLBCL, not otherwise specified) or high-grade B-cell lymphoma. * Received prior CD19-targeted chimeric antigen receptor (CAR) T-cell therapy. * Confirmed stable disease (SD) or progressive disease (PD) at the most recent imaging assessment (according to Lugano 2014 criteria) following CAR-T therapy. * Able to provide a formalin-fixed paraffin-embedded (FFPE) tumor tissue sample (fresh biopsy or archival specimen obtained before CAR-T therapy or after recent progression) with sufficient quantity and quality for immunohistochemistry (IHC) testing. * Confirmed CD20-positive tumor cells by central laboratory IHC testing. * Eastern Cooperative Oncology Group (ECOG) performance status score of 0, 1, or 2. * Adequate organ function (including bone marrow, liver, kidney, and heart). * Women of childbearing potential must agree to use highly effective contraception during the study and for a specified period after the last dose of study drug; male patients must agree to use effective contraception during the study and for a specified period after the last dose. * Voluntarily agreed to participate in the study, signed the written informed consent form, and willing to comply with the study visit schedule and other protocol requirements. Exclusion Criteria: * Prior treatment with glofitamab resulting in disease progression. * Known severe allergic reactions to any components of the study drugs. * Active central nervous system (CNS) lymphoma involvement. * Presence of a severe, uncontrolled active infection. * Presence of severe cardiovascular or cerebrovascular diseases, uncontrolled diabetes, or uncontrolled hypertension that, in the investigator's judgment, makes the patient unsuitable for study participation. * History of or current other malignancies (exceptions: adequately treated basal cell carcinoma of the skin, carcinoma in situ of the cervix, etc.). * Pregnant or breastfeeding women. * Positive for human immunodeficiency virus (HIV) antibody, or active hepatitis B virus (HBV) infection (HBsAg positive with HBV-DNA \> 1x10\^3 copies/mL), or active hepatitis C virus (HCV) infection (HCV antibody positive and HCV-RNA positive). * Any medical or psychiatric condition that might interfere with study execution or result interpretation, or place the patient at unacceptable risk. * Received other anti-tumor therapies (including chemotherapy, radiotherapy, immunotherapy, etc.) within 2 weeks prior to study enrollment, or have not recovered from toxicities of prior therapies to ≤ Grade 1 or baseline levels (excluding alopecia or other irreversible but non-clinically significant toxicities).